Study of ErChen decoction on the treatment of obesity polycystic ovary syndrome and obesity infertility
10.12206/j.issn.1006-0111.202105078
- VernacularTitle:二陈汤对肥胖型多囊卵巢综合征和肥胖型不孕的“异病同治”研究
- Author:
Mengcheng CAI
1
;
Yongsheng JIN
2
;
Chaoqin YU
2
;
Wen CHENG
2
;
Jin YU
2
;
Ling ZHOU
2
Author Information
1. Basic Medicine School, b. School of Pharmacy, c. Department of Traditional Chinese Medicine, Naval Medical University, Shanghai 200433.
2. null.
- Keywords:
phlegm-dampness;
infertility;
polycystic ovary syndrome;
molecular docking;
network pharmacology
- From:
Journal of Pharmaceutical Practice
2022;40(1):20-27
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the potential mechanism of Erchen decoction in the treatment of obese polycystic ovary syndrome and obese infertility, in order to provide theoretical basis for “treating different diseases with same method”. Methods The active ingredients and targets of Erchen decoction were obtained from TCMSP database, and the targets of obese polycystic ovary syndromes and obese infertility were obtained from GeneCard database. Active ingredient-target network was constructed by Cytoscape 3.7.1, and protein-protein interaction network and core target were obtained from STRING. GO and KEGG enrichment analysis were performed by Cytoscape 3.7.1 and online software. Results 125 ingredients and 218 targets of Erchen decoction were obtained. There were 2 783 target genes for obese infertility and 2 962 target genes for obese polycystic ovary syndrome. Erchen decoction has a total of 117 target genes in the treatment of obese infertility and obese polycystic ovary syndromes, which proves the principle of “treating different diseases with same method”. Potential active ingredients include quercetin, kaempferol, naringin, baicalin and formononetin. PPI showed that STAT3, JUN, AKT1, MAPK3, MAPK1, MAPK14, IL-6 and FOS were the core targets of “treating different diseases with same method”. Molecular docking results showed that quercetin, kaempferol, etc. had good binding ability with JUN. GO and KEGG enrichment analysis showed that AGE-RAGE signaling pathway, IL-17 signaling pathway and endocrine resistance might be the key pathways for the “treating different diseases with same method” of Erchen decoction. Conclusion Erchen decoction treating "different diseases with same method" involves same targets and same pathways, which can provide reference for future experimental research.
